NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
IGCS 2020 Annual Global Meeting – Abstract
Phase 1 Dose-Escalation Study of STRO-002, an anti-Folate Receptor alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum Resistant/Refractory Epithelial Ovarian Cancer (OC). Dr. Naumann is currently the Director of Minimally Invasive Surgery in...
Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
SOUTH SAN FRANCISCO, Calif., August 25, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Announces Two Executive Promotions to Vice President of Quality and Vice President of Manufacturing
Mr. Carlos Lugo promoted to Vice President of Quality and CMC Regulatory Operations Mr. Devendra Luhar promoted to Vice President of Manufacturing & Plant Operations SOUTH SAN FRANCISCO, Calif., August 11, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...
Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
SOUTH SAN FRANCISCO, Calif., August 10, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments
Encouraging STRO-002 Interim Phase 1 Clinical Data Presented at the AACR Virtual Meeting in April STRO-002 Preclinical Data Presented at 2020 AACR Virtual Annual Meeting II in June Suggests Synergy between STRO-002 and Immune Checkpoint Inhibitors STRO-001 Dose...
Open Letter from CEO, Bill Newell
Today, I want to clearly state, that America still has a very long way to go to fulfill the hard won promises of the Civil Rights era of the 60s. I was born in 1957 and so was first exposed to civil rights issues as a child. But I was from an aspiring middle class...
Bristol Myers Squibb Investor Series
June 25, 2020 at 11:30am ET WEBCAST View This Presentation June 22, 2020 at 11:30am ET WEBCAST View This Presentation
M1231: A First In-Class Bispecific ADC Targeting EGFR and MUC1 Presented by EMD Serono at American Association for Cancer Research (AACR) Virtual Meeting II on June 24, 2020 – Presentation
AACR requires pre-registration to access this presentation. Oral Presentation & Discussion, timestamp 1:43:36, expired link no longer available
American Association for Cancer Research (AACR) 2020 Virtual Meeting II – Abstract
STRO-002, An Anti-FolRα ADC, Demonstrates Immune-Modulating Properties and Potentiates PD-L1 Blockade Millicent Embry*, Sihong Zhou*, Christine Cheng, Janice Yu, Cristina Abrahams, Xiaofan Li, Jeff Hanson, Cuong Tran, Gang Yin, Shamim Ahmad, Krishna Bajjuri, Venita...
American Association for Cancer Research (AACR) 2020 Virtual Meeting II – Poster
STRO-002, An Anti-FolRα ADC, Demonstrates Immune-Modulating Properties and Potentiates PD-L1 Blackade Please Click the Link, STRO-002 AACR 2020 Poster to Enlarge Please click link to view, Poster Script Please click play button below to listen, Poster Narrative